Follow-up nerve conduction studies in CIDP after treatment with IGIV-C: Comparison of patients with and without subsequent relapse.

Abstract

INTRODUCTION:

Electrodiagnostic studies (EDX) are not performed routinely before treatment suspension in CIDP, and no data exist regarding their value in predicting clinical relapse.

METHODS:

Serial EDX (baseline and after IGIV-C therapy) were analyzed from subjects in the ICE clinical trial who responded to IGIV-C treatment and were subsequently re-randomized to placebo in an extension phase. Comparisons were made between subjects who relapsed and those who did not.

RESULTS:

A total of 55% (6/11) of the Relapse group had an increase in total number of demyelinating findings (DF) versus 8% (1/13) in the No Relapse group (P = 0.023). In the Relapse group, 100% had ≥ 1 new DF and 73% (8/11) had ≥ 4 new DF versus 60% (8/13) and 8% (1/13), respectively, in the No Relapse group.

CONCLUSIONS:

An increased total number of DF or the occurrence of ≥ 4 new DF may indicate a higher risk of clinical relapse after treatment cessation in IGIV-C-responsive patients.

• Authors: Russell L Chin, Chunqin Deng, Vera Bril, Hans-Peter Hartung, Ingemar S J Merkies, Peter D Donofrio, Pieter A Van Doorn, Marinos C Dalakas, Norman Latov
• Journal: Muscle & nerve (Muscle Nerve) Vol. 52 Issue 4 Pg. 498-502 (Oct 2015) ISSN: 1097-4598 [Electronic] United States
• PMID: 25728021 (Publication Type: Journal Article, Randomized Controlled Trial)
• Copyright: © 2015 Wiley Periodicals, Inc.

Chemical References

• Immunoglobulins, Intravenous
• Immunologic Factors

Topics

• Action Potentials (drug effects)
• Adult
• Aged
• Electrodiagnosis
• Female
• Follow-Up Studies
• Humans
• Immunoglobulins, Intravenous (therapeutic use)
• Immunologic Factors (therapeutic use)
• Male
• Middle Aged
• Neural Conduction (drug effects, physiology)
• Polyradiculoneuropathy, Chronic Inflammatory Demyelinating (physiopathology, therapy)
• Reaction Time
• Recurrence
• Treatment Outcome